Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2020

View Archived Issues

Presepsin may have prognostic utility for the stratification of patients at risk of severe COVID-19

HSK-26784 shows efficacy in multiple B lymphocyte-derived malignancy models

Discovery of novel PRMT5 inhibitor, ALG-0700043

Initiator Pharma obtains U.K. approval to begin phase IIa study of IP-2018

Enspryng approved in Japan for adults and children with NMOSD

FDA grants IND allowance for phase Ia/b study of CG-806 in AML

Positive data from phase III RHAPSODY study of rilonacept in recurrent pericarditis

Fibroblast growth factor receptor 4 inhibitors described by Guangdong Newopp Biopharmaceuticals

Autobahn Therapeutics presents new thyroid hormone receptor beta agonists

Xeomin botulinum toxin type A receives marketing approval in Japan

Korea Research Institute of Chemical Technology patents PDE9A inhibitors

FDA clears IND for RP-L401 gene therapy for infantile malignant osteopetrosis

Roche discovers anti-hepatitis B virus compounds

Boehringer Ingelheim and Hydra Biosciences present new TrpC5 antagonists

First phase I data presented for HM-15136

Topline data reported from phase III SURE1 study of sulopenem

Janssen presents preclinical data for first-in-class MALT1 inhibitor JNJ-6785663

COVID-19: study points to kinases as HIV combo falls flat for SARS-CoV-2

Topline results presented from phase I/II study of ITI-214 heart failure

Onoact approved for additional indication of tachyarrhythmia associated with sepsis in Japan

Vadadustat approved in Japan for the treatment of anemia due to CKD

AOBiome begins phase IIb study with B-244 for pruritus in atopic dermatitis

Ongentys tablets approved in Japan for patients with PD with motor fluctuations

Phase II topline data reported for tisotumab vedotin in recurrent or metastatic cervical cancer

RedHill gains U.K. clearance to begin phase II/III trial of opaganib in severe COVID-19

FDA approves Keytruda for first-line unresectable or metastatic MSI-H or dMMR colorectal cancer

TFF reports clinical progress with inhalation powder formulations of tacrolimus and voriconazole

FDA issues complete response letter for Intercept's obeticholic acid for NASH fibrosis

FDA approves Phesgo for HER2-positive breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...